

18 November 2021

ASX Announcement

ADALTA GRANTED SECOND US PATENT PROTECTING AD-214

MELBOURNE Australia, 18 November 2021: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is pleased to announce its second US patent relating to lead program, AD-214, has been granted by the United States Patent and Trademark Office.

United States Patent Number 11,142,588 is entitled “Polypeptides which bind C-X-C chemokine receptor type 4 (CXCR4) and methods of treating or reducing the risk of fibrosis and cancer”, is related to the earlier granted US Patent Number 10,538,596 and has the same expiration date of 8 January 2036.

The new patent protects the i-body sequence used in AdAlta’s lead product, AD-214, sequences similar to this, and pharmaceutical compositions containing these i-body sequences and their uses in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF), the lead indication for which AD-214 is being developed.

Patents are granted on a country-by-country basis, and this is the third patent to be granted under this application. The Australian version was granted in 2017 the first US patent in January 2020 and the Japanese version in May 2021. Claims are being pursued in other major markets including the European Union and China.

AdAlta’s CEO and Managing Director, Dr Tim Oldham said:

“This second patent strengthens AdAlta’s patent portfolio and in particular provides protection for AD-214 in one of the largest pharmaceutical and pulmonary fibrosis markets in the world. Strong intellectual property protection is essential to our partnering and commercialisation strategy.”

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
November 2021

Notes to editor

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today’s most challenging medical conditions.



The i-body technology mimics the shape and properties of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. A second target implicated in fibrosis is in discovery research.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a revenue generating agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development. It also has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies to bring new hope to patients with cancer.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au